OpenAI Unveils AI Model for Drug Discovery, Challenging Google

Deep News04-17 05:01

OpenAI is launching an early version of an artificial intelligence (AI) model designed to accelerate drug discovery, joining the race among technology companies to demonstrate AI's potential in driving further scientific breakthroughs.

The developer of ChatGPT announced on Thursday that the model, named GPT-Rosalind, is targeted at life sciences research. It can assist in extracting insights from vast datasets and translating scientific research into patient-facing medical applications. OpenAI stated that the model will initially be available as a research preview to select enterprise clients. Early users include pharmaceutical company Amgen, vaccine manufacturer Moderna, and the nonprofit Allen Institute for bioscience research.

OpenAI, Anthropic, and Alphabet's Google are increasingly focusing on AI applications in science and healthcare, including aiding new drug development and analyzing personal medical data.

Following the announcement, shares of companies involved in drug discovery experienced significant declines. IQVIA Holdings dropped as much as 3.2%, Charles River Laboratories International Inc. fell 2.6%, while Recursion Pharmaceuticals and Schrodinger both saw declines exceeding 5%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment